The application prospects and current situation of Lorlatinib in the treatment of ALK-positive non-small cell lung cancer

In recent years, the incidence rate of non-small cell lung cancer (NSCLC) has increased year by year, becoming one of the most common malignant tumors worldwide. Lorlatinib, a new drug for the treatment of ALK-positive metastatic non-small cell lung cancer, has gradually attracted attention. As a targeted therapy, this drug not only improves the survival rate of patients, but also improves the quality of life. In 2025, Lorlatinib, as a third-generation ALK/ROS1 dual-target inhibitor, not only takes the lead in controlling brain metastasis and delaying drug resistance, but also shows good long-term safety and controllable adverse reactions.

xa0

1. Update on pharmacological mechanism: targetingALK and ROS1 dual pathways

Lorlatinib is a highly selectiveATP competitive inhibitor that can effectively inhibit the signaling pathways activated by ALK (anaplastic lymphoma kinase) and ROS1 fusion protein. Its molecular structure has a unique bicyclic amino substituent, which can penetrate the blood-brain barrier and produce significant inhibitory effects on brain metastases. This property makes lorlatinib one of the few oral ALK inhibitors with central nervous system activity.

A 2025 NEJM report pointed out that new crystallographic analysis revealed that lorlatinib binds more stably at ALK kinase region sites (G1202R, L1196M, etc.), reversibly blocks the mutation activation pathway, and significantly reduces the incidence of late-stage drug resistance mutations. This lays the molecular basis for its long-term efficacy.

xa0

II.Clinical breakthrough:Interpretation of five-year follow-up data of the CROWN study

The CROWN study is a landmark Phase III clinical trial in the field of ALK-positive NSCLC. Its five-year follow-up data published in 2024 has completely rewritten the treatment landscape of advanced lung cancer. The study showed that in the Asian subgroup without brain metastases at baseline, the 5-year cumulative incidence of brain metastases in the lorlatinib treatment group was 0%. This data is revolutionary in clinical practice. What deserves attention is the data of the Chinese patient population - a subgroup analysis led by Chinese scholars shows that the 5-year PFS rate of Chinese ALK-positive NSCLC patients after receiving first-line treatment with lorlatinib is as high as 70%, which is more advantageous than the global population data.

From a mechanistic perspective, lorlatinib's molecular design breakthroughs are reflected in three aspects:1) small molecular weight (428.4 Da) and optimized lipophilicity to achieve efficient blood-brain barrier penetration; 2) not affected by drug efflux mediated by P-glycoprotein and breast cancer resistance protein (BCRP); 3) broad-spectrum inhibitory effect on ALK kinase domain mutation sites, especially covering refractory drug-resistant mutations such as G1202R and I1171T. These characteristics enable lorlatinib to demonstrate an intracranial objective response rate of 92% in the control of brain metastases, which is 40% higher than the second-generation ALK inhibitor.

3.Dosage and usage instructions

According to the instructions, the standard recommended dosage of lorlatinib is as follows:

1. Standard dose for adults: 100 mg orally once a day.

2. How to take: It can be taken with a meal or on an empty stomach. It is recommended to swallow the whole tablet at a fixed time every day. Do not break or grind it.

3. Treatment course and efficacy evaluation: Continue medication until disease progression or unacceptable adverse reactions occur.

4. Suggestions for dosage adjustment:

When moderate or severe adverse reactions occur (such as hyperlipidemia or cognitive impairment), the dosage can be reduced to 75 mg/day or 50 mg/day.

Contraindicated use in combination with potent CYP3A inducers (such as carbamazepine, rifampicin) to avoid reduction in drug efficacy.

5. Special groups: People with mild to moderate damage to liver and kidney function can use it at regular doses, while people with severe damage need individualized adjustments.

Lorlatinib tablets are usually 100 mg in size and should be stored away from light and moisture at room temperature. Patients need to regularly monitor blood lipids, liver enzymes and cognitive status under the guidance of a doctor.

xa0

IV.The significance to Chinese patients and the medical insurance environment

1.Background of Domestic Medical Insurance Inclusion

In China, as an original research drug "lorlatinib tablets" have entered the Category B medical insurance reimbursement catalog. The common specifications are 25 mg×90 tablets and 100 mg×30 tablets, and the price per box is about 20,000 yuan. The price of the Hong Kong original research version is about RMB 30,000 to RMB 50,000.

Enrolling in Medicare means patients can reduce their financial burden, but they still need to consider the costs of long-term use, toxicity management, and monitoring. When selecting drugs, patients and their families should pay attention to: whether they are from formal channels, consistency of drug ingredients, quality of imitations, and regulatory status.

2. Overseas drug selection

The original Turkish version of lorlatinib is about 10,000 yuan. There is also a generic version of 100 mg × 30 tablets produced by a Lao pharmaceutical factory on the market. The price per box may be around 1,000 yuan (exchange rate changes may cause the price to fluctuate). Against this background, the accessibility of lorlatinib in clinical practice in China coexists with challenges.

xa0

5.Clinical practice: starting from“who uses it”, “when to use it” and “how to use it”

【Who should use it】Suitable for everyone

Adults Patients with ALK-positive metastatic NSCLC (especially those with FDA/China-approved ALK test positivity). Suitable for patients with brain metastasis or expected to have a high risk of brain metastasis. For those who have not yet received ALK inhibitor treatment, early intervention may be considered.

[When to use] Suggested treatment timing

For treatment-naïve patients, lorlatinib should be considered rather than waiting for other ALK inhibitors to fail;

It is also an important option for those who have used first/second generation ALK inhibitors ALK inhibitors and have progressed;

The advantages are more obvious when the patient has good organ function, can monitor toxicity, and has long-term management conditions.

【How to use】Dosage, monitoring, management

The recommended dose is: once daily100 mg, with or without food, until disease progression or intolerable toxicity.

Strictly monitor: blood lipids, liver and kidney function, neurological/cognitive status, hydration and swelling, and cardiovascular status.

When significant toxicity occurs, the dose should be reduced/interrupted promptly, and the risks/benefits should be discussed with the patient.

Emphasis on multidisciplinary collaboration: including medical oncology, neurology, nutrition, imaging, and nursing teams.

【Patient Education and Compliance】

Take medication regularly, and do not stop taking medication without authorization or make up a double dose;

Recognize common adverse reactions and guide patients to proactively report them: such as cognitive changes, neurological symptoms, rapid weight gain, and severe edema.

Nutrition/exercise intervention: Controlling blood lipids and weight, and maintaining good living habits can help reduce some toxicity.

xa0

V.Summary: Milestone in a new era of treatment

Lorlatinib, as a representative drug for targeted therapy of ALK-positive NSCLC, not only showed breakthrough results in 5-year follow-up, but also has medical insurance coverage in China, making it move from a "high-end target drug" to a "clinically accessible targeted solution." Although there are still challenges in long-term toxicity management, cost affordability, treatment sequence optimization, etc., lorlatinib undoubtedly represents an important milestone in a new era of treatment from the perspective of global clinical data, improvement of patient quality of life, and changes in the policy environment.

References:

Pfizer Inc. Lorlatinib Clinical Development Update 2025.

The New England Journal of Medicine. CROWN Trial Five-Year Follow-up on Lorlatinib, 2025.

ClinicalTrials.gov. Studies: NCT05093582, NCT05641121.

National Cancer Institute (NCI). ALK-positive Lung Cancer Treatment Overview, 2025.

Medscape. Lorlatinib: Latest Updates on Resistance and CNS Efficacy, 2025.